Tech for diverting blood around diseased arteries
LimFlow’s minimally invasive technology diverts blood around diseased arteries in the leg, bringing it into one of the tibial veins so that it can deliver blood and oxygen to starved tissue of the foot.
The company raised $33.5 million in a Series C funding round in 2018 and is currently conducting the Promise II trial on patients at risk of lower limb amputation. –SW
Investors include: Sofinnova Partners, Bpifrance, Balestier